{"nct_id":"NCT02301156","title":"Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","status_verified_date":"2022-04","start_date":"2015-01-27","start_date_type":"ACTUAL","primary_completion_date":"2020-04-01","primary_completion_date_type":"ACTUAL","completion_date":"2020-04-01","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["TGTX"]}